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Case report
A 13-year-old male adolescent with severe 
respiratory distress presented to a medical outpatient 
department. He was admitted to the adult ward with 
suspected Pneumocyctis jirovecii pneumonia. He was 
known to be HIV-infected and on antiretroviral therapy (ART) for 
approximately 10 years, with a CD4 count of 10 cells/µL (0.1%) and a 
viral load of 1.5 million copies/mL (Fig. 1).
On further enquiry, it was noted that his mother had died from 
an HIV-related illness when he was 3 years old; he was subsequently 
adopted by his maternal aunt. History of nevirapine exposure for 
prevention of mother-to-child transmission (PMTCT) was not 
known. During a routine clinic visit, at age 3, he was diagnosed as 
HIV-positive and was commenced on ART (stavudine, lamivudine 
and efavirenz). 
The patient’s ART regimen was changed at his local clinic to 
second-line therapy (zidovudine, didanosine, lopinavir) when he was 
5 years old. The reason for the change was not documented; however, 
during that time his aunt commenced shift work at night, and a 
neighbour was given the responsibility of administering medication 
to the patient for almost a year. After adherence counselling, his 
aunt resumed normal working hours and took responsibility for 
administering ART, after which the patient maintained HIV viro-
logical suppression to undetectable levels with reasonable CD4 count 
recovery, until 2 years ago. 
As is common in our setting, the carer had not yet disclosed the 
HIV status to the patient. Here, the patient believed that his daily 
medication comprised antituberculosis drugs to prevent him from 
becoming ‘sick’. A school friend pointed out that the medication 
was ART. His aunt had noticed initial subtle behavioural change, 
which progressed to overt aggression, violent tendencies towards his 
co-learners at school and substance abuse. He stopped taking ART 
and left his aunt’s home.
During the course of the latest admission for P. jirovecii pneu-
monia, the patient and his aunt underwent extensive counselling and 
the former agreed to recommence ART (zidovudine, lamivudine, 
lopinavir/ritonavir), under supervision of his aunt. Six weeks later 
his viral load was 700 000 copies/mL and an HIV drug-resistance 
genotype test showed mutations to protease inhibitors (M46I, I54V, 
V82A), nucleoside reverse-transcriptase inhibitors (NRTIs) (M41L, 
D67N, K70T, T215Y, K219Q) and non-nucleoside reverse-transcriptase 
inhibitors (NNRTIs) (K103N). During the course of infancy, childhood 
and adolescence, he had accumulated extensive mutations to all 
available classes of antiretroviral medications, limiting current and 
future treatment options. Based on the patient’s resistance testing, he 
was commenced on tenofovir/emtricitabine (Truvada), daurinavir/
ritonavir and raltegravir. He currently remains virologically suppressed.
We present a case that highlights the complexity of managing 
long-term adolescent survivors of HIV acquired through vertical 
transmission. We describe the impact of non-disclosure of HIV 
status on medication adherence, and the impact of non-adherence on 
acquisition of ART drug resistance.
Urgent unmet needs in adolescent HIV care include the challenge 
of lifelong ART, limited safe, effective and robust drug options, and 
lack of co-formulated antiretroviral drugs appropriate for once-
daily dosing.[1] While the development of a single-pill treatment 
regimen has resulted in high ART adherence and acceptability, with 
substantial improvements in quality of care in HIV-infected adults, 
this option is not yet available to children and adolescents.[2]
What is the burden of disease in 
adolescents and children? 
Globally, adolescence is defined as the period of development 
between the ages of 10 and 19 years, represents the fastest growing age 
group of HIV-infected people, and accounts for 5.9% of the burden 
of HIV.[1] Approximately 2 500 of the 6 300 new HIV infections that 
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occur daily worldwide, are in adolescents and youth 15 - 24 years 
of age, while a third of these are in children <15 years owing largely 
to vertical transmission.[1] Temporal trends analysis of adolescent 
HIV prevalence conducted between 2006 and 2012 in South Africa 
(SA), while showing decreases from 22.4% to 19.3% (15 - 24 age 
group), 13.7% to 14.4% (15 - 19 age group) and 28.0% to 24.2% 
(20 - 24 age group),[3] still remains alarmingly high. The expanding 
disease burden among adolescents underscores the need for a greater 
understanding and suitable adaptation of HIV care and treatment 
services to adequately meet the needs of this patient population. 
Notwithstanding unprecedented investments in ART scale-up and 
delivery in the past decade, published literature shows that adolescents 
are less likely to access HIV care and remain in care or achieve virological 
suppression.[4] Despite guidance in the management of adolescent 
ART issued by the WHO in 2013 there have, however, been serious 
impediments to reducing delays in the initiation of appropriate ART, 
in supporting adherence to treatment and in retention of adolescents 
in care.[1] Currently, approximately 90% of the estimated 3 million 
children living with HIV globally[1] reside in sub-Saharan Africa[5] – 
only 27% of those who require ART receive it.[1] Furthermore, in SA 
only 45% of the 369 000 HIV-infected children aged 10 - 14 years, and 
14.3% of the 720 000 aged 15 - 24 years, currently receive ART.[6] This 
may be due to HIV-exposed children often not receiving conclusive 
HIV test results, poor linkage to appropriate paediatric care, and lack 
of facilities that specifically cater for children.[1]
As in adults, the benefits of ART in HIV-positive children and 
adolescents include a decreased risk of death, improved growth, 
better immune function, and a marked reduction in infectious 
complications.[7] The benefits and risks need to be considered in 
the context of safe and sustainable therapeutic options for lifelong 
ART. In 2013, WHO HIV guidelines recommended that adult ART 
regimens and dosing schedules be applied to adolescents >35 kg. 
These recommendations did not take into consideration the pubertal 
changes and growth delays that affect ART metabolism, a lack of 
clarity guiding the timing of transition from weight-based to age-
based dosing, and a lack of efficacy and safety data on co-formulated 
agents.[8] HIV resistance in children occurs as transmitted drug 
resistance (TDR), which is either vertical (from mother to child) 
or horizontal (through a sexual partner), or has been acquired, and 
results from poor ART adherence.
The US Reaching for Excellence in Adolescent Care and Health 
(REACH) study evaluating disease progression, which was conducted 
in HIV-positive adolescents infected through sexual behaviour or 
injection drug use, found that only 41% of adolescents aged 12 - 
19 years reported >95% adherence to ART.[9] Factors associated 
with poor adherence included depression, pill burden, advanced 
HIV status, alcohol use, and dropping out of school.[10] In addition, 
Murphy et al.[9] reported that only 28.3% of adolescents reported 
>95% adherence in the previous month. Barriers to adherence 
included ART toxicity and complications with regard to integrating 
pill-taking with day-to-day routines.[7,9] In another US study, the 
Pediatric AIDS Clinical Trial Group (PACTG) 381, of 120 adolescents 
(aged 11 - 22 years) infected via high-risk behaviour and receiving 
triple ART therapy, only 44 (37%) stayed on study treatment for the 
3 years of observation. Twenty-nine (24%) reached and maintained viral 
suppression, and poor adherence was the main predictor of virological 
failure.[11]
With increases in the number of adolescents on ART, sustaining 
optimal ART adherence has emerged as a major challenge to maintaining 
ongoing AIDS-free survival and prevention of sexual transmission for this 
group. Antiretroviral regimens are often complex, require good adherence 
for efficacy, and may lead to the development of viral resistance due to 
treatment non-adherence (defined as <95% of medication taken, or 
>1 missed dose per week) or suboptimal levels of antiretroviral agents. 
Furthermore, in many HIV-endemic resource-limited settings, 
the future impact of perinatal HIV transmission strategies, including 
nevirapine or zidovudine mono- or dual therapy on acquisition of 
resistance to non-nucleoside-based first-line ART regimens, has not 
been fully quantified. Our case highlights themes that have already 
emerged from the literature in developed countries. A meta-analysis 
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Fig. 1. CD4 count and viral load responses to ART during 13 years of follow-up of a child with vertically acquired HIV (VL = viral load; D4t = stavudine; 
3TC = lamivudine; EFV = efavirenz; AZT = zidovudine; ddi = didanosine; LPV = lopinavir; RTV = ritonavir). 
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on ART adherence among children, adolescents and young adults 
living with HIV found variable and suboptimal adherence rates. This 
was especially the case among adolescents, where adherence was 
highly dependent on complex relationships between individuals, their 
families, society and other treatment regimen-related factors.[10] 
A recently published systematic review of 15 studies assessing correlates 
of ART adherence among adolescents in low- and middle-income 
countries, highlights several factors associated with challenges in ART 
adherence and potential areas for intervention. Emerging themes for 
suboptimal adherence across all studies include gender and knowledge of 
serostatus, influence of family structure, impact of onerous ART regimens 
– including route of administration – and attitudes about medication, 
healthcare and environmental factors, such as rural versus urban and 
missed appointments.[12] Other studies cite the following psychosocial risk 
factors for poor ART adherence: being orphaned, mental health problems, 
changes of guardianship, and absence of parental and social support.[5]
As seen with the case presented, major hindrances to adolescent 
adherence are the lack of autonomy and reliance on adult caregivers 
to access care, complying with clinic visits, collecting medication and 
adhering to the dosage schedule.[11] These are further confounded by 
issues surrounding status disclosure, autonomy and maturity. Decisions 
around HIV status disclosure differ in those with horizontally acquired 
infection compared with vertical infection. However, evidence suggests 
that non-disclosure is associated with various negative outcomes.[5] Often, 
status disclosure is deferred until children approach cognitive maturity 
and puberty, but the decision to disclose is dependent on the family 
and caregivers, especially as adolescent status disclosure simultaneously 
discloses the status of the biological mother.[5,11] Non-adherence to 
ART is further complicated by behavioural experimentation typical of 
this phase of development. The ability of HIV-infected adolescents to 
successfully transition from reliance on adults towards autonomy in 
taking responsibility for their illness, managing adherence to drugs and 
visiting clinics is further complicated during this stage of development 
by the display of behavioural patterns that deviate from expected or 
prescribed patterns,[5] making close observation and interventions for 
non-adherence necessary.[11]
The recently revised 2015 SA Paediatric ART treatment guidelines 
advocate an abacavir-based regimen for first-line ART in children <15 years 
or <40 kg, which may then be changed to tenofovir disoproxil fumarate at 
15 years of age and weight ≥40 kg in those with an undetectable viral 
load. The use of abacavir-based regimens in paediatric populations is 
thought to aid in slowing down acquired drug resistance, especially 
in children who require extended periods of ART owing to the high 
genetic barrier to resistance[11] and favourable cross-resistance pattern. 
Conversely, a multicohort analysis of early virological response in 9 453 
SA children <16 years of age showed lower virological suppression rates 
at 6 months in those receiving an abacavir-based lopinavir/ritonavir-
containing regimen compared with those receiving a stavudine-based 
lopinavir/ritonavir-containing regimen (54% v. 70%, p<0.0001).[13] 
Furthermore, alternative agents such as tenofovir disoproxil fumarate, 
while recommended for use in children >2 years of age by the US Food 
and Drug Administration, are currently registered in SA for use in 
patients >12 years of age owing to safety concerns and lack of available 
paediatric formulations.[14] The WHO has, however, highlighted the 
risk of tenofovir-related renal and bone toxic effects, and recommends 
specific monitoring of children and prepubertal adolescents receiving 
tenofovir.[5] Tenofovir alafenamide, a novel tenofovir prodrug currently 
being evaluated in Phase 2b and 3 trials in adolescents, achieves a 90% 
reduction in plasma tenofovir concentrations. This drug has also shown 
improved renal and bone safety profiles, while maintaining equivalent 
virologial suppression rates in adults compared with tenofovir disoproxil 
fumarate-containing regimens.[2]
Recent ART scale-up in SA has allowed more people to access care, 
but may inevitably engender HIV drug resistance, thereby limiting 
the benefits of treatment. Increases in paediatric HIV drug resistance 
in resource-limited settings have been driven by limited access 
to routine viral load monitoring, limited availability of paediatric 
drugs for second-line therapy and complexities related to PMTCT, 
paediatric care and ART adherence, as seen in the presented case.[1] 
A recently published review of drug-resistant mutation prevalence 
rates after first-line ART failure among children in resource-limited 
settings, showed mutation rates of 80% for NRTIs, 88% for NNRTIs 
and 54% for boosted protease inhibitors.[15]
A survey conducted in 18 African countries reported an increase 
in TDR, primarily driven by NNRTI resistance, with moderate levels 
of TDR (5 - 15%) being documented in KwaZulu-Natal.[15] This is 
of concern, as this drug class forms the backbone of first-line ART 
regimens and prophylaxis for PMTCT.[15]
What are the research gaps in 
understanding ART resistance in 
children?
HIV-infected children and adolescents remain at high risk of disease 
progression and death. Insufficient attention has been directed towards the 
creation of specialised centres offering HIV testing and care. Evaluating 
the impact of services that prioritise the needs of children and adolescents 
in care on long-term ART adherence and retention is warranted. SA has 
recently celebrated tremendous success in improving PMTCT, offering all 
HIV-infected pregnant women immediate ART access. This implies that 
most children who were exposed to HIV during the perinatal period have 
also been exposed to maternal ART. The magnitude of HIV prevalence 
in the sexually active age group and the growing risk of transmitted 
ART resistance emphasise the need for research into the use of pre-ART 
resistance testing in children and adolescents initiating or changing ART. 
Observation of acquisition rates of ART resistance is especially important 
to inform future drug sequencing, especially in high-burden settings 
offering a programmatic approach. 
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